Table 5.
Psychiatric symptoms and medication use at any time (baseline+follow-up) in subjects who had at least 1 year of follow-up (Cohort 2)
| ChEI | ChEI+memantine | χ2 | p Value | |
|---|---|---|---|---|
| No of subjects | 289 | 140 | ||
| Psychiatric symptoms | ||||
| Major depression (%) | 60 (21) | 28 (20) | 0.12 | 0.72 |
| Psychosis (%) | 194 (67) | 88 (63) | 0.76 | 0.38 |
| Aggression (%) | 89 (31) | 39 (28) | 0.38 | 0.53 |
| Agitation (%) | 249 (86) | 123 (88.5) | 0.25 | 0.61 |
| Psychiatric medication | ||||
| Antidepressants (%) | 156 (54) | 71 (51) | 0.40 | 0.52 |
| Tricyclics/MAOI (%) | 4 (1) | 2 (1) | 5.23 | 0.26 |
| SSRI/third generation (%) | 152 (53) | 69 (46) | ||
| Antipsychotics (%) | 56 (19) | 23 (15) | 0.54 | 0.46 |
| Typical (%) | 9 (3) | 0 | 5.25 | 0.26 |
| Atypical (%) | 47 (16) | 23 (16) | ||
| Sedatives, anxiolytics and hypnotics (%) | 52 (18) | 11 (8) | 7.73 | 0.005 |
| Other treatments | ||||
| Multivitamins (%) | 135 (47) | 68 (49) | 0.13 | 0.71 |
| Vitamin E≥400 IU (%) | 168 (58) | 53 (38) | 0.87 | 0.35 |
| Lipid-lowering agents (%) | 71 (25) | 59 (42) | 13.7 | <0.001 |
| ASA ≥81 mg (%) | 95 (33) | 40 (28) | 0.20 | 0.002 |
| Estrogens (n=635) (%) | 35 (18) | 16 (18) | 0.04 | 0.83 |
ASA, acid acetylsalicylic; ChEI, cholinesterase inhibitor; MAOI, monoamine oxidase inhibitors; SSRI, selective serotonin-reuptake inhibitors.